Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russian Federation.
Novosibirsk State University, Novosibirsk, Russian Federation.
Anticancer Res. 2021 Jul;41(7):3371-3387. doi: 10.21873/anticanres.15125.
BACKGROUND/AIM: We compared the therapeutic efficacy of two recently developed experimental anticancer technologies: 1) in situ vaccination based on local immunotherapy with CpG oligonucleotides and anti-OX40 antibodies to activate antitumor immune response and 2) "Karanahan" technology [from the Sanskrit kāraṇa ('source') + han ('to kill')] based on the combined injection of cyclophosphamide and double-stranded DNA to eradicate cancer stem cells.
The anticancer approaches were compared on three types of mouse malignant tumors with different grades of immunogenicity: weakly immunogenic carcinoma Krebs-2, moderately immunogenic Lewis carcinoma, and highly immunogenic A20 В-cellular lymphoma.
Our results indicated that in situ vaccination was the most effective against the highly immunogenic tumor А20. In addition, "Karanahan" demonstrated high efficiency in all types of tumors, regardless of their immunogenicity or size.
"Karanahan" therapy showed higher efficacy relative to in situ vaccination with CpG oligonucleotides and anti-OX40 antibodies.
背景/目的：我们比较了两种最近开发的实验性抗癌技术的疗效：1）基于局部免疫疗法的 CpG 寡核苷酸和抗 OX40 抗体的原位疫苗接种，以激活抗肿瘤免疫反应；2）基于环磷酰胺和双链 DNA 联合注射的“Karanahan”技术[源自梵语 kāraṇa（“来源”）+han（“杀死”）]，以消灭癌症干细胞。
在三种免疫原性不同的小鼠恶性肿瘤类型上比较了抗癌方法：弱免疫原性的 Krebs-2 癌、中等免疫原性的 Lewis 癌和高度免疫原性的 A20 B 细胞淋巴瘤。
我们的结果表明，原位疫苗接种对高度免疫原性的 A20 肿瘤最有效。此外，“Karanahan”疗法在所有类型的肿瘤中均显示出高效性，无论其免疫原性或大小如何。
与 CpG 寡核苷酸和抗 OX40 抗体的原位疫苗接种相比，“Karanahan”疗法显示出更高的疗效。
